CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereof
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10773/37150 |
Resumo: | Bladder cancer (BC) is the most common malignancy of the urinary tract, with high recurrence rates. Aberrant glycosylation of the proteins and lipids of the bladder cancer cells leads to the generation of truncated O-glycans, which have been linked to tumour progression and poor prognosis. Although truncated O-glycans, such as Tn and STn, are overexpressed in several carcinomas, they are also present in non-malignant disorders and, thus, challenge the development of targeted cancer immunotherapies. Therefore, we propose glycoproteome as a strategy to achieve cancer-specific structures for novel therapeutic treatments. Following this alignment, CD44s was associated with invasion and worst prognosis and the study of CD44s O-glycoforms, such as CD44s-Tn/STn may allow to overcome the lack of cancer specificity of CD44s. Accordingly, a glycovaccine based in glycopeptides CD44s-Tn/STn was generated by single-pot enzymatic synthesis, attending to induce an immune response against tumours CD44s-Tn/STn positive. Furthermore, the glycopeptides synthesized by us present equal glycosylation sites compared with bladder tumour cells, reinforcing the importance of glycovaccines in cancer treatment. The pre-clinical study demonstrates that glycoconjugated vaccine plus MPLA adjuvant do not cause cellular toxicity and it can generate humoral immune response. Despite these results indicating a promising strategy to improve cancer treatment, excessive costs associated with manufacturing remain a major drawback. Building on this, a lentiviral strategy was implemented to modify target cell lines in order to create genetically modified mammalian platforms for large-scale production of human glycopeptides. To conclude, this work established the molecular bases for the development of a well characterized multivalent glycovaccines aiming to improve anti-cancer immunotherapies settings. |
id |
RCAP_670a1f04b93b5969bfcd8e6d1cc8499c |
---|---|
oai_identifier_str |
oai:ria.ua.pt:10773/37150 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereofCancerGlycosylationGlycansTn antigenSialyl-Tn (STn) antigenCD44 proteinGlycoconjugatesCancer vaccinesCell factoriesBladder cancer (BC) is the most common malignancy of the urinary tract, with high recurrence rates. Aberrant glycosylation of the proteins and lipids of the bladder cancer cells leads to the generation of truncated O-glycans, which have been linked to tumour progression and poor prognosis. Although truncated O-glycans, such as Tn and STn, are overexpressed in several carcinomas, they are also present in non-malignant disorders and, thus, challenge the development of targeted cancer immunotherapies. Therefore, we propose glycoproteome as a strategy to achieve cancer-specific structures for novel therapeutic treatments. Following this alignment, CD44s was associated with invasion and worst prognosis and the study of CD44s O-glycoforms, such as CD44s-Tn/STn may allow to overcome the lack of cancer specificity of CD44s. Accordingly, a glycovaccine based in glycopeptides CD44s-Tn/STn was generated by single-pot enzymatic synthesis, attending to induce an immune response against tumours CD44s-Tn/STn positive. Furthermore, the glycopeptides synthesized by us present equal glycosylation sites compared with bladder tumour cells, reinforcing the importance of glycovaccines in cancer treatment. The pre-clinical study demonstrates that glycoconjugated vaccine plus MPLA adjuvant do not cause cellular toxicity and it can generate humoral immune response. Despite these results indicating a promising strategy to improve cancer treatment, excessive costs associated with manufacturing remain a major drawback. Building on this, a lentiviral strategy was implemented to modify target cell lines in order to create genetically modified mammalian platforms for large-scale production of human glycopeptides. To conclude, this work established the molecular bases for the development of a well characterized multivalent glycovaccines aiming to improve anti-cancer immunotherapies settings.O cancro da bexiga (CB) é a malignidade mais frequente do trato urinário, apresentando elevada taxa de recidiva. A glicosilação aberrante das proteínas e lípidos das células tumorais da bexiga leva à geração de O-glicanos truncados, que têm estado ligados à progressão do tumor e ao seu mau prognóstico. Embora os O-glicanos truncados, como o Tn e o STn, estejam sobreexpressos em vários carcinomas, estes estão também presentes em doenças não malignas e, portanto, desafiam o desenvolvimento de imunoterapias oncológicas dirigidas. Por conseguinte, propomos o estudo do glicoproteoma como estratégia para alcançar estruturas específicas relacionadas com o cancro, de modo a desenvolver novos tratamentos terapêuticos. Seguindo este alinhamento, a isoforma CD44s foi associada à invasão e ao mau prognóstico e o estudo das O-glicoformas CD44s, tais como CD44s-Tn/STn podem permitir a superação da falta de especificidade tumoral apresentada pela CD44s. Consequentemente, uma glicovacina à base de glicopéptidos CD44s-Tn/STn foi gerada por síntese enzimática single one-pot, com o objetivo de induzir uma resposta imunológica contra tumores CD44s-Tn/STn positivos. Além disso, os glicopéptidos sintetizados por nós apresentam locais de glicosilação iguais às células tumorais da bexiga, reforçando a importância destes no tratamento do cancro. O estudo pré-clínico demonstra que a vacina glicoconjugada mais o adjuvante MPLA não causa toxicidade celular e pode gerar resposta imunológica humoral. Apesar destes resultados indicarem uma estratégia promissora para o melhoramento do tratamento do cancro, os custos excessivos associados ao fabrico desta continuam a ser um grande inconveniente. Com base nisto, foi implementada uma estratégia lentiviral para modificar as linhas celulares alvo, a fim de criar plataformas de origem mamífera geneticamente modificadas para a produção em grande escala de glicopéptidos humanos. Para concluir, este trabalho estabeleceu as bases moleculares para o desenvolvimento de glicovacinas multivalentes bem caracterizadas, com o objetivo de melhorar os cenários de imunoterapias anti tumorais.2024-12-12T00:00:00Z2022-12-12T00:00:00Z2022-12-12info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10773/37150engFerreira, Eduardo da Silvainfo:eu-repo/semantics/embargoedAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-02-22T12:11:15Zoai:ria.ua.pt:10773/37150Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:07:36.182860Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereof |
title |
CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereof |
spellingShingle |
CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereof Ferreira, Eduardo da Silva Cancer Glycosylation Glycans Tn antigen Sialyl-Tn (STn) antigen CD44 protein Glycoconjugates Cancer vaccines Cell factories |
title_short |
CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereof |
title_full |
CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereof |
title_fullStr |
CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereof |
title_full_unstemmed |
CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereof |
title_sort |
CD44 glycovaccine for bladder cancer: synthesis, pre-clinical validation and biotechnological solution thereof |
author |
Ferreira, Eduardo da Silva |
author_facet |
Ferreira, Eduardo da Silva |
author_role |
author |
dc.contributor.author.fl_str_mv |
Ferreira, Eduardo da Silva |
dc.subject.por.fl_str_mv |
Cancer Glycosylation Glycans Tn antigen Sialyl-Tn (STn) antigen CD44 protein Glycoconjugates Cancer vaccines Cell factories |
topic |
Cancer Glycosylation Glycans Tn antigen Sialyl-Tn (STn) antigen CD44 protein Glycoconjugates Cancer vaccines Cell factories |
description |
Bladder cancer (BC) is the most common malignancy of the urinary tract, with high recurrence rates. Aberrant glycosylation of the proteins and lipids of the bladder cancer cells leads to the generation of truncated O-glycans, which have been linked to tumour progression and poor prognosis. Although truncated O-glycans, such as Tn and STn, are overexpressed in several carcinomas, they are also present in non-malignant disorders and, thus, challenge the development of targeted cancer immunotherapies. Therefore, we propose glycoproteome as a strategy to achieve cancer-specific structures for novel therapeutic treatments. Following this alignment, CD44s was associated with invasion and worst prognosis and the study of CD44s O-glycoforms, such as CD44s-Tn/STn may allow to overcome the lack of cancer specificity of CD44s. Accordingly, a glycovaccine based in glycopeptides CD44s-Tn/STn was generated by single-pot enzymatic synthesis, attending to induce an immune response against tumours CD44s-Tn/STn positive. Furthermore, the glycopeptides synthesized by us present equal glycosylation sites compared with bladder tumour cells, reinforcing the importance of glycovaccines in cancer treatment. The pre-clinical study demonstrates that glycoconjugated vaccine plus MPLA adjuvant do not cause cellular toxicity and it can generate humoral immune response. Despite these results indicating a promising strategy to improve cancer treatment, excessive costs associated with manufacturing remain a major drawback. Building on this, a lentiviral strategy was implemented to modify target cell lines in order to create genetically modified mammalian platforms for large-scale production of human glycopeptides. To conclude, this work established the molecular bases for the development of a well characterized multivalent glycovaccines aiming to improve anti-cancer immunotherapies settings. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-12-12T00:00:00Z 2022-12-12 2024-12-12T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10773/37150 |
url |
http://hdl.handle.net/10773/37150 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/embargoedAccess |
eu_rights_str_mv |
embargoedAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137730540601344 |